<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767880</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-305-20</org_study_id>
    <nct_id>NCT04767880</nct_id>
  </id_info>
  <brief_title>Acute Metabolic Effects of Pre-meal Consumption of Whey in Women at Risk of Gestational Diabetes Mellitus</brief_title>
  <official_title>Acute Metabolic Effects of Pre-meal Consumption of Whey in Women at Risk of Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of our study is to investigate the metabolic effects of whey protein (whey&#xD;
      protein isolate, WPI, (Lacprodan® ISO.Water. from Arla Foods Ingredients) compared to placebo&#xD;
      when consumed by women in risk of gestational diabetes mellitus (GMD) 30 minutes prior to an&#xD;
      oral glucose tolerance test (OGTT). We will also investigate any changes in substrate&#xD;
      metabolism and energy expenditure using indirect calorimetry. Differences in hunger and&#xD;
      satiety parameters as well as rate of gastric emptying will also be assessed. Furthermore, we&#xD;
      will investigate the glucose response when the women consume the intervention at home in&#xD;
      their own environment 30 minutes before breakfast in various doses (placebo, 10, 15, 20, 30 g&#xD;
      whey). The women will be monitored with continuous glucose monitors, activity monitors and&#xD;
      all meals will be provided.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Singleblind, randomized, crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded to the intervention and placebo in the laboratory setting.&#xD;
Quadruple (Participants, care providers, investigators and outcome assessors) Participants, care providers, investigators and outcome assessors will be blinded to the placebo and varying doses of whey in the home setting.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration differences in blood glucose following an OGTT</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in glucose independent peptide (GIP)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in glucagon like peptide 1 (GLP-1)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in glucagon</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in insulin</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in c-peptide</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in free fatty acids (FFA)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in ghrelin</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in leptin</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration differences in amino acids (AA)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying rate (Concentration differences in blood paracetamol/acetaminophen)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure (REE) (Resting Metabolic Rate)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory quotient (RQ)</measure>
    <time_frame>3 hours following the OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported appetite</measure>
    <time_frame>3 hours following the OGTT and 3 hours following breakfast</time_frame>
    <description>A visual analogue scale ranging from &quot;not at all&quot; to &quot;extremely&quot; will be used to assess Hunger, Fullness, Satiety, Desire, Prospective consumption (Quantity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>5 days</time_frame>
    <description>A combined accelerometer and heart rate monitor will be used to measure heart rate (beats/minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>5 days</time_frame>
    <description>A combined accelerometer and heart rate monitor will be used to estimate energy expenditure (kCal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>5 days</time_frame>
    <description>A combined accelerometer and heart rate monitor will be used to measure activity (counts/minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous glucose measurements (CGM)</measure>
    <time_frame>5 days</time_frame>
    <description>Time in range, concentration differences in interstitial fluid glucose 3 hours following breakfast, glycemic variability, mean glucose, daily maximum glucose, estimated HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Whey</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast in the women's own environment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be ingested 30 min. prior to an OGTT (3 hours). The placebo will also be ingested 30 min prior to breakfast in the women's own environment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey</intervention_name>
    <description>Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))</description>
    <arm_group_label>Whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo contains &lt;1 kcal and 0 g protein</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referred to screening for Gestational Diabetes Mellitus by week 24-30&#xD;
&#xD;
          -  BMI 20-35&#xD;
&#xD;
          -  Normal blood pressure&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Special dietary regimes &gt; 1 month at time of inclusion e.g. ketogenic diet&#xD;
&#xD;
          -  Daily intake of protein supplements&#xD;
&#xD;
          -  Milk allergy or phenylketonuria&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Medication with effect on glucose metabolism e.g. steroid&#xD;
&#xD;
          -  Do not speak or understand Danish&#xD;
&#xD;
          -  Gemelli&#xD;
&#xD;
          -  Polycystic Ovarian Syndrome&#xD;
&#xD;
          -  PI finds the patient unfit (like mental illness, too nervous or other)&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;6 mmol/l)&#xD;
&#xD;
          -  Severe chronic illness&#xD;
&#xD;
          -  Depression&#xD;
&#xD;
          -  Severe nausea/vomiting&#xD;
&#xD;
          -  Non-breakfast eaters&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per G Ovesen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Clinical Medicine, Aarhus University and Department of Gynecology and Obstetrics and Steno Diabetes Center Aarhus, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stine Smedegaard, MD</last_name>
    <phone>20714671</phone>
    <email>stinesmedegaard@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per G Ovesen, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

